H
Harriet Mayanja-Kizza
Researcher at Makerere University
Publications - 243
Citations - 8163
Harriet Mayanja-Kizza is an academic researcher from Makerere University. The author has contributed to research in topics: Tuberculosis & Mycobacterium tuberculosis. The author has an hindex of 43, co-authored 221 publications receiving 6804 citations. Previous affiliations of Harriet Mayanja-Kizza include Mulago Hospital & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
A blood RNA signature for tuberculosis disease risk: a prospective cohort study.
Daniel E. Zak,Adam Penn-Nicholson,Thomas J. Scriba,Ethan G. Thompson,Sara Suliman,Lynn M. Amon,Hassan Mahomed,Mzwandile Erasmus,Wendy Whatney,Gregory D. Hussey,Deborah Abrahams,Fazlin Kafaar,Tony Hawkridge,Suzanne Verver,E. Jane Hughes,Martin O. C. Ota,Jayne S. Sutherland,Rawleigh Howe,Hazel M. Dockrell,W. Henry Boom,Bonnie Thiel,Tom H. M. Ottenhoff,Harriet Mayanja-Kizza,Amelia C. Crampin,Katrina Downing,Mark Hatherill,Joe Valvo,Smitha Shankar,Shreemanta K. Parida,Stefan H. E. Kaufmann,Gerhard Walzl,Alan Aderem,Willem A. Hanekom +32 more
TL;DR: The whole blood tuberculosis risk signature prospectively identified people at risk of developing active tuberculosis, opening the possibility for targeted intervention to prevent the disease.
Journal ArticleDOI
Outcomes of Cryptococcal Meningitis in Uganda Before and After the Availability of Highly Active Antiretroviral Therapy
Andrew Kambugu,David B. Meya,Joshua Rhein,Meagan O’Brien,Edward N. Janoff,Allan R. Ronald,Allan R. Ronald,Moses R. Kamya,Harriet Mayanja-Kizza,Merle A. Sande,Paul R. Bohjanen,David R. Boulware +11 more
TL;DR: Significant CM-associated mortality persists, despite the administration of amphotericin B and HIV therapy, because of the high mortality rate before receipt of HAART and because of immune reconstitution inflammatory syndrome-related complications after HAART initiation.
Journal ArticleDOI
A study of the safety immunology virology and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis.
Robert S. Wallis,Peter Kyambadde,John L. Johnson,Libby Horter,Rodney Kittle,Monika Pohle,Constance Ducar,Monica Millard,Harriet Mayanja-Kizza,Christopher C. Whalen,Alphonse Okwera +10 more
TL;DR: Etanercept can be safely administered during the initial treatment of pulmonary tuberculosis, and trends towards superior responses to tuberculosis treatment were evident in etanercept-treated subjects in body mass, performance score, number of involved lung zones, cavitary closure, and time to sputum culture conversion.
Journal ArticleDOI
Four-Gene Pan-African Blood Signature Predicts Progression to Tuberculosis
Sara Suliman,Ethan G. Thompson,Jayne S. Sutherland,January Weiner rd,Martin O. C. Ota,Smitha Shankar,Adam Penn-Nicholson,Adam Penn-Nicholson,Bonnie Thiel,Mzwandile Erasmus,Mzwandile Erasmus,Jeroen Maertzdorf,Fergal J. Duffy,Philip C. Hill,E. Jane Hughes,E. Jane Hughes,Kim Stanley,Katrina Downing,Katrina Downing,Michelle Fisher,Michelle Fisher,Joe Valvo,Shreemanta K. Parida,Gian D. van der Spuy,Gian D. van der Spuy,Gerard Tromp,Gerard Tromp,Ifedayo M. O. Adetifa,Simon Donkor,Rawleigh Howe,Harriet Mayanja-Kizza,W. Henry Boom,Hazel M. Dockrell,Tom H. M. Ottenhoff,Mark Hatherill,Mark Hatherill,Alan Aderem,Willem A. Hanekom,Willem A. Hanekom,Thomas J. Scriba,Thomas J. Scriba,Stefan H. E. Kaufmann,Daniel E. Zak,Gerhard Walzl,Gerhard Walzl +44 more
TL;DR: A simple whole blood‐based PCR test to predict TB in recently exposed household contacts from diverse African populations has potential for implementation in national TB contact investigation programs.
Journal ArticleDOI
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy.
Moses R. Kamya,Harriet Mayanja-Kizza,Andrew Kambugu,Sabrina Bakeera-Kitaka,Fred C. Semitala,Patricia Mwebaze-Songa,Barbara Castelnuovo,Petra Schaefer,Lisa A. Spacek,Anne Gasasira,Elly Katabira,Robert Colebunders,Thomas C. Quinn,Allan R. Ronald,David L. Thomas,Adeodata Kekitiinwa +15 more
TL;DR: In this article, the authors identified predictors of viral failure and documented genotypic mutations in a subset of patients with viral failure after 12 months on antiretroviral therapy (ART).